Pioneering genetic therapies for neurodegenerative disease
Neurological disease remains the largest cause of disability and second leading cause of mortality, worldwide, but life-changing therapies could be on the horizon.
With another 12 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.
If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, Beam and Prime Medicine to name a few.
Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.